Pulmonary function changes following helical tomotherapy in patients with inoperable, locally advanced non-small cell lung cancer

被引:2
作者
Vekens, K. [1 ]
Verbanck, S. [1 ]
Collen, C. [2 ]
Storme, G. [2 ]
Barbe, K. [3 ]
De Ridder, M. [2 ]
Vanderhelst, E. [1 ]
机构
[1] Univ Hosp Brussel, Resp Div, Laarbeeklaan 101, B-1090 Brussels, Belgium
[2] Univ Hosp Brussel, Dept Radiotherapy, Brussels, Belgium
[3] Vrije Universiteit Brussel, Dept BioStat, Med Informat, Brussels, Belgium
关键词
Pulmonary function indices; Radiation damage; Low-dose radiation; IMRT; Inoperable NSCLC; INTENSITY-MODULATED RADIOTHERAPY; RADIATION-THERAPY; CONCURRENT CHEMORADIOTHERAPY; CONFORMAL RADIOTHERAPY; DOSE-ESCALATION; TOXICITY; STANDARDIZATION; CHEMOTHERAPY; PACLITAXEL; PERFUSION;
D O I
10.1007/s00066-019-01489-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To evaluate alterations in pulmonary function indices after helical tomotherapy and explore potential associations with biologically corrected dosimetric parameters. Patients and methods In 64 patients with inoperable locally advanced non-small cell lung cancer, pulmonary function tests before and within 6 months after radiotherapy were evaluated retrospectively. In the case of concurrent chemotherapy a total dose of 67.2 & x202f;Gy was delivered, otherwise 70.5 & x202f;Gy was provided. In 44 patients, late pulmonary function changes (>= 6 months after radiotherapy) could also be assessed. Results In the entire patient group, there were significant declines in forced expiratory volume in 1s (FEV1) (average change -4.1% predicted; P & x202f;= 0.007), in forced vital capacity (FVC) (-4.9% predicted; P & x202f;= 0.002), total lung capacity (TLC) (-5.8% predicted; P & x202f;= 0.0016) and DLCO (diffusing capacity of the lung for carbon monoxide corrected for hemoglobin level) (-8.6% predicted; P & x202f;< 0.001) during the first 6 months. Corresponding FEV1, FVC, TLC and DLCO declines in the subgroup with late measurements (after 11.3 months on average) were -5.7, -7.4, -7.0, -9.8% predicted. A multivariate analysis including V-5 & x202f;(Gy), V-10 & x202f;(Gy), V-20 & x202f;(Gy), V-40 & x202f;(Gy), V-60 & x202f;(Gy), mean lung dose (MLD), gross tumor volume (GTV) and planning target volume (PTV) as potential covariates showed that GTV was the most consistent contributor, being significant for increment FEV1 (P & x202f;= 0.003), increment FVC (P & x202f;= 0.003), increment TLC (P & x202f;= 0.001) and increment DLCO (P & x202f;= 0.01). V-5 & x202f;(Gy) or V-10 & x202f;(Gy) did not contribute to any of the lung function changes. Conclusions The decline in pulmonary function indices after helical tomotherapy was of similar magnitude to that observed in studies reporting the effect of conformal radiotherapy on lung function. Diffusion capacity was the parameter showing the largest decrease following radiation therapy as compared to baseline and correlated with gross tumor volume. None of the alterations in pulmonary function tests were associated with the lung volume receiving low-dose radiation.
引用
收藏
页码:142 / 150
页数:9
相关论文
共 28 条
  • [1] THE EFFECT OF IRRADIATION ON LUNG-FUNCTION AND PERFUSION IN PATIENTS WITH LUNG-CANCER
    ABRATT, RP
    WILLCOX, PA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (04): : 915 - 919
  • [2] LUNG-CANCER IN PATIENTS WITH BORDERLINE LUNG FUNCTIONS - ZONAL LUNG PERFUSION SCANS AT PRESENTATION AND LUNG-FUNCTION AFTER HIGH-DOSE IRRADIATION
    ABRATT, RP
    WILLCOX, PA
    SMITH, JA
    [J]. RADIOTHERAPY AND ONCOLOGY, 1990, 19 (04) : 317 - 322
  • [3] Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Kurata, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    Carpeno, J. de Castro
    Faivre-Finn, C.
    Reck, M.
    Vansteenkiste, J.
    Spigel, D. R.
    Wadsworth, C.
    Melillo, G.
    Taboada, M.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (24) : 2342 - 2350
  • [4] Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer
    Auperin, Anne
    Le Pechoux, Cecile
    Rolland, Estelle
    Curran, Walter J.
    Furuse, Kiyoyuki
    Fournel, Pierre
    Belderbos, Jose
    Clamon, Gerald
    Ulutin, Hakki Cuneyt
    Paulus, Rebecca
    Yamanaka, Takeharu
    Bozonnat, Marie-Cecile
    Uitterhoeve, Apollonia
    Wang, Xiaofei
    Stewart, Lesley
    Arriagada, Rodrigo
    Burdett, Sarah
    Pignon, Jean-Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2181 - 2190
  • [5] Routine Use of Intensity-Modulated Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer Is Neither Choosing Wisely Nor Personalized Medicine
    Ball, David
    Mac Manus, Michael
    Siva, Shankar
    Plumridge, Nikki
    Bressel, Mathias
    Kron, Tomas
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (13) : 1492 - +
  • [6] Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study
    Bradley, Jeffrey D.
    Paulus, Rebecca
    Komaki, Ritsuko
    Masters, Gregory
    Blumenschein, George
    Schild, Steven
    Bogart, Jeffrey
    Hu, Chen
    Forster, Kenneth
    Magliocco, Anthony
    Kavadi, Vivek
    Garces, Yolanda I.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Cliff
    Wynn, Raymond B.
    Koprowski, Christopher
    Meng, Joanne
    Beitler, Jonathan
    Gaur, Rakesh
    Curran, Walter, Jr.
    Choy, Hak
    [J]. LANCET ONCOLOGY, 2015, 16 (02) : 187 - 199
  • [7] TOXICITY AND OUTCOME RESULTS OF A CLASS SOLUTION WITH MODERATELY HYPOFRACTIONATED RADIOTHERAPY IN INOPERABLE STAGE III NON-SMALL CELL LUNG CANCER USING HELICAL TOMOTHERAPY
    Bral, Samuel
    Duchateau, Michael
    Versmessen, Harijati
    Engels, Benedikt
    Tournel, Koen
    Vinh-Hung, Vincent
    De Ridder, Mark
    Schallier, Denis
    Storme, Guy
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (05): : 1352 - 1359
  • [8] Toxicity Report of a Phase 1/2 Dose-Escalation Study in Patients With Inoperable, Locally Advanced Nonsmall Cell Lung Cancer With Helical Tomotherapy and Concurrent Chemotherapy
    Bral, Samuel
    Duchateau, Michael
    Versmessen, Harijati
    Verdries, Douwe
    Engels, Benedikt
    De Ridder, Mark
    Tournel, Koen
    Collen, Christine
    Everaert, Hendrik
    Schallier, Denis
    De Greve, Jacques
    Storme, Guy
    [J]. CANCER, 2010, 116 (01) : 241 - 250
  • [9] INTERPRETATION OF BRONCHODILATOR RESPONSE IN PATIENTS WITH OBSTRUCTIVE AIRWAYS DISEASE
    BRAND, PLP
    QUANJER, PH
    POSTMA, DS
    KERSTJENS, HAM
    KOETER, GH
    DEKHUIJZEN, PNR
    SLUITER, HJ
    [J]. THORAX, 1992, 47 (06) : 429 - 436
  • [10] Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial
    Chun, Stephen G.
    Hu, Chen
    Choy, Hak
    Komaki, Ritsuko U.
    Timmerman, Robert D.
    Schild, Steven E.
    Bogart, Jeffrey A.
    Dobelbower, Michael C.
    Bosch, Walter
    Galvin, James M.
    Kavadi, Vivek S.
    Narayan, Samir
    Iyengar, Puneeth
    Robinson, Clifford G.
    Wynn, Raymond B.
    Raben, Adam
    Augspurger, Mark E.
    MacRae, RobertM.
    Paulus, Rebecca
    Bradley, Jeffrey D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (01) : 56 - +